Amicus Therapeutics (NASDAQ: EVLO) and Evelo Biosciences (NASDAQ:EVLO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.
This table compares Amicus Therapeutics and Evelo Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Amicus Therapeutics and Evelo Biosciences’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Amicus Therapeutics||$36.93 million||62.07||-$284.00 million||($2.92)||-4.15|
|Evelo Biosciences||N/A||N/A||-$28.04 million||N/A||N/A|
Evelo Biosciences has lower revenue, but higher earnings than Amicus Therapeutics.
Insider & Institutional Ownership
80.5% of Evelo Biosciences shares are held by institutional investors. 2.9% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a summary of current ratings for Amicus Therapeutics and Evelo Biosciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Amicus Therapeutics presently has a consensus price target of $19.67, indicating a potential upside of 62.27%. Evelo Biosciences has a consensus price target of $25.50, indicating a potential upside of 94.66%. Given Evelo Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Evelo Biosciences is more favorable than Amicus Therapeutics.
Evelo Biosciences beats Amicus Therapeutics on 7 of the 10 factors compared between the two stocks.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Evelo Biosciences Company Profile
Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn's colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.